On December 5, 2019 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that it will host an R&D event and live webcast featuring several key opinion leaders ("KOLs") to discuss the Company’s advanced antibody-based therapeutic pipeline and recent clinical and corporate developments on Wednesday, December 11, 2019 from 12:00-2:00pm EST in New York City (Press release, Y-mAbs Therapeutics, DEC 5, 2019, View Source [SID1234551972]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will feature presentations by KOLs Dr. Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering Cancer Center ("MSK"), Dr. Kim Kramer, M.D., MSK, and Dr. Jaume Mora, M.D., Ph.D., SJD Barcelona Children’s Hospital, who will discuss the current treatment landscape and unmet medical needs for treating patients with high-risk pediatric neuroblastoma and other solid tumors. Drs. Modak, Kramer, and Mora will be available to answer questions at the conclusion of the event.
Y-mAbs management will also provide an in-depth overview of the Company’s broad and advanced product pipeline as well as a review of recent corporate and clinical developments. Y-mAbs is advancing two pivotal-stage product candidates, naxitamab and omburtamab, targeting tumors that express GD2 and B7-H3, respectively.
Members of the media and public may access the event via a live webcast.